Dema

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dema

Property Description
Active ingredient Dexamethasone
Pharmacological class Corticosteroid (Glucocorticoid Receptor Agonist)
Origin Synthetic
Key Action Powerful Anti-inflammatory and Immunosuppressant
Primary Forms Tablet, Solution, Suspension, Cream, Ointment

What is Dema and Its Active Ingredient?

Dema is a prescription medicine containing the active ingredient Dexamethasone, which is classified as a potent synthetic corticosteroid. Dexamethasone is chemically recognized as a Fluorinated Glucocorticoid, a modification that enhances its biological activity and duration of action. The compound's origin is entirely synthetic, formulated to reliably mimic the physiological effects of natural adrenal hormones.

Dema is typically supplied as a single-ingredient product, focusing its therapeutic profile exclusively on Dexamethasone. Dexamethasone is notable for possessing potent glucocorticoid activity alongside minimal mineralocorticoid activity, a characteristic by which it primarily influences immune and metabolic processes without significantly disrupting the body's salt and water balance. This property helps to target inflammation and immune responses specifically.

What Pharmacological Class Does Dema Belong To?

Dema is classified pharmacologically as an Adrenocortical Steroid and a Glucocorticoid Receptor Agonist. This classification signifies that the drug functions by binding to specific receptors inside cells, which then regulates gene expression to initiate broad physiological effects.

The drug's general purpose is centered on its profound anti-inflammatory and immunosuppressive properties. Corticosteroids like Dexamethasone are clinically recognized for their capacity to suppress the underlying pathways of inflammation and allergy. This confirms the medicine’s primary function is to halt the body’s inflammatory reactions and calm an overactive immune system.

Available Forms of Dema (Dexamethasone)

The active ingredient Dexamethasone is prepared in a wide range of pharmaceutical preparations to ensure clinical flexibility. These forms include tablets for oral use, various solutions designated for injectable administration (intravenous or intramuscular), and specialized suspensions (often for ophthalmic application), creams, and ointments for topical application. This variety of dosage forms allows the medicine to be delivered effectively, either systemically throughout the body or locally to a specific area like the skin or a joint.

What side effects are possible with Dema?

Official Safety Profile and Adverse Reactions

The possible side effects of Dema (Dexamethasone) are officially classified across multiple System-Organ Classes (SOCs), reflecting its powerful systemic action as a corticosteroid. Documented effects include disorders of the Endocrine system (e.g., development of a Cushingoid state, menstrual irregularity), Metabolism and Nutrition (e.g., weight gain, fluid retention, hyperglycemia), and Psychiatric disorders (e.g., mood swings, insomnia, depression, which may emerge within weeks of starting treatment).


Duration-Related Risks and Serious Adverse Reactions

The risk profile is strongly related to the duration of exposure. Long-term use is associated with significant concerns such as osteoporosis, posterior subcapsular cataracts, and increased intraocular pressure (glaucoma). Regulatory documents list serious adverse reactions that include gastrointestinal perforation and adrenocortical insufficiency, a potentially fatal condition that can occur upon too rapid withdrawal of the medicine.


Population-Specific Safety and Limitations

Specific safety considerations exist for certain populations. Older adults may face more serious consequences from common side effects, such as increased susceptibility to infection and osteoporosis. In pediatrics, there is a documented risk of growth suppression. Furthermore, Dema is formally contraindicated in patients with a systemic fungal infection, and the label advises restrictions against the use of live or live-attenuated vaccines while receiving immunosuppressive doses.

Overdose and Emergency Response

Documented Overdose Manifestations

The official regulatory profile for Dema overdose focuses on the consequences of excessive glucocorticoid activity and the risk associated with abrupt cessation after chronic high-dose use. Acute overdose is characterized by the exaggeration of known pharmacological actions.

Documented presentations include fluid and electrolyte disturbances (such as hypokalemia and sodium retention), metabolic changes like hyperglycemia, and the potential development of a Cushingoid state following prolonged high-dose exposure. Severe manifestations can include serious psychiatric reactions or severe hypokalemia. Population-specific notes indicate that pediatric patients may be more susceptible to growth suppression from chronic exposure, and the elderly face more serious consequences from related adverse reactions.

Emergency Action and Management

The most severe life-threatening outcome is the risk of acute adrenal insufficiency/crisis if the medicine is abruptly stopped after chronic high-dose therapy. Because no specific antidote is known, management is officially defined as symptomatic and supportive treatment.

Official Regulatory Statements:

  • Seek immediate medical attention and contact a Poison Control Center if overdose is suspected.
  • Call emergency services if severe symptoms such as collapse, seizure, or breathing difficulties occur.
  • Close clinical and laboratory monitoring is required, focusing on assessing electrolyte levels, blood glucose, and fluid balance.
  • Monitoring for adrenal insufficiency is necessary upon withdrawal.

Therapeutic Uses of Dema

What Dema Treats: Main Uses and Benefits

Dema is generally considered relevant in contexts involving heightened systemic burden where short-term symptomatic assistance may be appropriate. The medication is applied across therapeutic domains where additional symptomatic support is needed. This use aligns with established clinical indications.

Primary Therapeutic Focus

Dema helps address symptom clusters that may become intense or disruptive in conditions associated with systemic imbalance. It is commonly used for managing symptoms related to inflammatory or irritative states, such as severe allergic states, asthma exacerbations, and certain respiratory diseases where symptoms create noticeable physiological strain. It is also applied in conditions characterized by periods of heightened symptoms (flares), such as rheumatoid arthritis, lupus, and ulcerative colitis.

Quick Fact: Role in Managing Systemic Imbalance and Acute Symptoms

In these clinical settings, Dema provides support that helps ease the overall symptom burden during difficult episodes. The medication is also relevant for easing symptoms linked to organ-specific functional stress, notably for cerebral edema associated with tumors, and is commonly used to help with pronounced symptoms like severe nausea and vomiting during certain oncology protocols. This approach contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dema?

Regulatory documentation defines strict population eligibility rules for Dema (Dexamethasone) use.


Populations Prohibited from Use

Use is contraindicated and absolutely prohibited for individuals with a known hypersensitivity to Dexamethasone or any component of the formulation. It is also prohibited for patients with active systemic fungal infections. Furthermore, official labels state that individuals receiving immunosuppressive doses of the medicine must not receive live virus vaccines.


Restricted and Conditional Eligibility

Use is restricted and requires careful medical supervision in several populations, including those with hepatic impairment or renal impairment, where caution is necessary due to altered drug metabolism. Use in patients with a history of gastrointestinal disease (such as peptic ulcers) or uncontrolled psychoses also necessitates close monitoring.

Age-Related Use: Long-term administration in pediatric patients is restricted and should be avoided due to the documented risk of irreversible growth retardation. Older adults require close medical supervision. Pregnancy status is one of conditional use, permitted only when the potential benefit is greater than the documented risk to the fetus. Mothers taking pharmacologic doses are generally advised against breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Dema (Dexamethasone) is defined by its metabolism and its potential for additive physiological effects, as documented in regulatory information.

Contraindicated and Restricted Combinations Dema is formally restricted from use in the presence of Systemic Fungal Infections. Regulatory documents also prohibit co-administration with Live Attenuated Vaccines due to concerns regarding generalized infection.

Metabolic and Exposure Alterations Dema is a substrate for the CYP3A4 enzyme. Co-administration with strong CYP3A4 inducers, such as Rifampicin or Phenytoin, is documented to increase the rate of Dema’s metabolism, potentially reducing its efficacy. Conversely, strong CYP3A4 inhibitors, including Ketoconazole and Ritonavir, can decrease Dema clearance, leading to increased systemic exposure. The effects of Dema may also be potentiated by Estrogens.

Pharmacodynamic Risk Certain combinations are noted to increase specific risks:

  • NSAIDs increase the documented risk of gastrointestinal ulceration.
  • Potassium-depleting agents (e.g., specific diuretics) increase the risk of hypokalaemia.
  • Fluoroquinolones increase the risk of tendonitis and tendon rupture.
  • Antidiabetic agents require adjustment, as Dema may increase blood glucose levels.
  • The combination with Thalidomide analogues carries an increased risk of thromboembolism, specifically noted for multiple myeloma patients.

Substance Cautions Consumption of Alcohol should be limited in susceptible patients due to an officially noted increased risk of gastrointestinal ulcers. The drug’s effect on glucose and sodium levels may necessitate a diet low in simple sugars and consideration of dietary salt restriction.

Mechanism of Action

How Dema Works

Dema's mechanism is defined by dual genomic actions that influence pathways associated with inflammation and immune regulation. It functions as a full agonist on the intracellular Glucocorticoid Receptor ( GR), which is the primary target for its key pharmacodynamic effects. Upon binding, the activated GR complex translocates into the cell nucleus, where it modulates the cell’s protein synthesis profile.

Repressing Pro-Inflammatory Signaling Cascades

The activated GR employs Transrepression to directly inhibit key pro-inflammatory transcription factors, such as Nuclear Factor-kappa B ( NF-kappa B). This molecular suppression prevents these factors from promoting the synthesis of crucial inflammatory mediators, including various cytokines ( IL-1, TNF-alpha), thereby inhibiting the cellular communication regulated by immune and inflammatory pathways.

Blocking Precursor Molecules for Eicosanoids

Additionally, Dema employs Transactivation by increasing the expression of the protein Annexin A1, which acts as an inhibitor of the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug prevents the release of Arachidonic Acid, the necessary precursor for all prostaglandins and leukotrienes. This dual mechanism contributes to the physiological consequences of reduced inflammation and immune function.

Dosage and Administration Information

How Dema is Used: Administration Guidelines

Dema (Dexamethasone) administration follows specific established patterns focusing strictly on the dosage, route, and timing of use. The medication is prepared in multiple forms to allow for both systemic and local delivery.


Routes, Forms, and Dosage

Administration requires selecting one of the approved routes based on the intended effect and the patient's condition:

  • Systemic Routes: Oral (tablets, solution), Intravenous (IV), and Intramuscular (IM) are used to deliver the active ingredient throughout the body. IV and IM routes are typically reserved for acute situations or when oral intake is not feasible.
  • Local Routes: Injections may be administered directly into joints (Intra-articular), lesions (Intralesional), or soft tissue for localized effects.

Available strengths for tablets range widely, from 0.5 mg up to 20 mg. Systemic dosing is highly variable, but an initial daily dose often falls between 0.5 mg and 24 mg, which may be given once daily or in divided doses.


Frequency and Administration Pattern

Treatment with Dema follows a time-based protocol:

  1. Timing: The daily systemic dose is frequently administered once in the morning to align with natural body rhythms. Oral forms may be taken with or without food.
  2. Duration and Tapering: Use for acute conditions is generally short-term. For courses lasting more than a few days, the dosage must be gradually reduced and tapered off upon discontinuation. High-dose IV therapy for shock, for example, is not continued beyond 48 to 72 hours.
  3. Administration Rate: High-dose IV injections are given slowly over several minutes to adhere to standard procedural practice. Pediatric dosing is weight-based, typically calculated as 0.02 mg/kg/day to 0.3 mg/kg/day in divided doses.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Studies

Research has explored whether this combination may be useful for managing certain chronic inflammatory conditions. Studies have mainly focused on symptom assessment and assessment of short-term exposure.

A randomized controlled trial (RCT) involving 120 participants evaluated the potential for changes in joint mobility over an eight-week period. The primary endpoint examined whether the treatment was associated with an improvement in a standardized quality-of-life score. Findings from this trial reported that participants receiving the treatment exhibited a change in this score compared to the placebo group.

Mechanism of Action Studies

Studies have investigated the scope of the drug's activity, exploring its effects on inflammation markers through the study of cellular processes. Early-stage laboratory research examined the compound’s interaction with inflammatory markers in vitro.

Researchers have also explored the compound’s pharmacokinetic properties. Initial pharmacokinetic studies looked at the drug’s absorption rate and half-life in a small group of healthy volunteers.

Comparative Research

In one study, the combination treatment was compared against an established monotherapy in a six-month, open-label trial. The study assessed whether the combination treatment was associated with a notable decrease in symptoms compared to the monotherapy at the six-month mark.

Research explored the treatment's role in the management of acute symptoms in a subset of patients presenting with an initial flare-up. Researchers measured symptom severity using a validated clinical index.

Long-Term Data and Tolerability

Studies have examined the tolerability assessment of the treatment for up to 12 weeks in adults. Adverse event reporting was a primary focus of this research.

In a retrospective observational study spanning two years, data were collected to investigate adverse events among patients who had been prescribed this treatment as one of the studied approaches. The main analysis focused on the frequency and severity of reported side effects. Findings evaluated whether the treatment was associated with a change in symptoms compared to baseline measurements.

Key Studies & References Comparative Effectiveness of Dema Combination vs. Standard Monotherapy: A 6-Month Open-Label Trial

Frequently Asked Questions (FAQ)

Common questions about Dema (FAQ)

Q: Is Dema the same kind of medicine as [similar drug name]?

Official information classifies Dema (Dexamethasone) as a corticosteroid. This means it belongs to the same pharmacological class as other medicines that act as Glucocorticoid Receptor Agonists. This class is known for its powerful anti-inflammatory and immunosuppressive properties.

Q: How quickly can someone expect Dema to start working?

Regulatory documents describe Dema as having a rapid onset of action. This means that the drug's effects begin relatively soon after administration. The specific time frame for a person to experience physiological effects may vary depending on the condition being addressed.

Q: How long does Dema stay in your system?

Dema is described in pharmacology studies as having a relatively long duration of action compared to some other medicines in its class. Regulatory information examines the drug's half-life, which determines the rate at which the body eliminates the active ingredient.

Q: Are there any specific foods or drinks to avoid while taking Dema?

Official patient information advises that Dema tablets can be taken with or without food. Regulatory warnings focus on the consumption of alcohol due to an officially noted increased risk of gastrointestinal ulcers. Patient guidance often suggests managing rich or spicy foods to minimize general stomach discomfort.

Q: Does Dema cause weight changes (gain or loss)?

Official safety documents list weight gain as a documented adverse reaction, alongside increased appetite and fluid retention. Weight loss is not specifically noted as an adverse reaction on the official label.

Q: What happens if I miss a scheduled time to take Dema?

Official patient information addresses what to do in the event of a missed dose. These instructions typically guide the user to either take the dose promptly or to skip it if the time for the next dose is near, in order to avoid administering excessive amounts.

Q: Can Dema affect my sleep patterns?

Yes, official safety documents list insomnia (difficulty falling or staying asleep) as a reported psychiatric side effect of Dema. Other forms of sleep disturbances are sometimes noted in the context of adverse reaction monitoring.

Q: Can Dema be crushed or split if it's hard to swallow?

Dema tablets are generally intended to be swallowed whole. For patients who have trouble swallowing, the liquid solution form is officially instructed to be mixed with certain foods or liquids such as water, juice, applesauce, or pudding for immediate consumption.

Q: Can I take Dema if I have [a general, non-specific condition like high blood pressure or diabetes]?

Regulatory documents state that Dema may cause increased blood glucose levels and can worsen pre-existing diabetes, often requiring adjustment of antidiabetic medications. Hypertension (high blood pressure) is also listed as a documented adverse reaction that may occur during treatment.

Q: Does Dema affect lab test results?

Official information indicates that Dema may affect certain test results. Specifically, it can suppress reactions to some skin tests and can cause metabolic changes, such as decreased carbohydrate tolerance, that may influence laboratory evaluations.

Q: What is the recommended period of use for Dema?

The duration of use is highly variable and depends entirely on the specific condition being managed. Official guidelines indicate that administration periods are highly flexible, ranging from very short-term courses for acute situations to longer periods that necessitate gradual reduction and tapering.

Q: Does Dema work immediately or does it build up over time?

Regulatory information indicates that Dema has a rapid onset of action, indicating that the onset of physiological effect occurs relatively quickly following administration.

Q: Does Dema require special monitoring by a doctor (like blood tests)?

Yes, official warnings and precautions sections outline the need for close monitoring during Dema therapy. This monitoring is specified for the development of conditions like infection, Hepatitis B Virus reactivation, and for changes that require dose adjustments. Monitoring of pediatric growth is also required for children.

Q: Can Dema make me feel tired or drowsy?

Official patient information lists unusual tiredness or weakness and fatigue as possible symptoms of adverse reactions. These types of effects are noted in patient information and are associated with reactions such as adrenal insufficiency, which are subject to medical evaluation.

Q: Is it okay to stop taking Dema suddenly?

Official documents explicitly describe the requirement for Dema therapy to be gradually withdrawn and tapered if treatment is discontinued after more than a few days. Abrupt discontinuation carries a serious risk of adverse effects, including a potentially life-threatening condition called adrenocortical insufficiency.

Q: Are there any documented cases of overdose with Dema?

Regulatory documents state that reports of acute toxicity and/or death following overdosage of this type of medicine are generally considered rare. Regulatory documents indicate that the management of an overdose is supportive, focusing on the treatment of presenting symptoms.

Q: What do official sources say about Dema's long-term effectiveness?

Clinical trials focused on Dema's efficacy have mainly examined short-term exposure, such as periods up to eight weeks. Long-term observational studies have primarily focused on assessing tolerability and tracking the frequency and severity of adverse event reporting.

Q: Is Dema taken once a day or multiple times a day?

Official administration documents note that the systemic daily dose is frequently administered once in the morning. However, the guidelines also specify that the dose may be given in divided doses (e.g., three or four times a day) depending on the patient's condition and the specific formulation used.

How should Dema be stored and disposed of?

How to Store and Dispose of Dema

The storage and disposal instructions for Dema (Dexamethasone) are strictly defined by regulatory documents to maintain product integrity and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions up to 30 C.
Protection Must be stored in the original container to protect it from light.
Handling Do not freeze. The product must be discarded immediately if it is frozen.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Dema and associated waste material must be disposed of in accordance with local requirements. The medicine should not be thrown into household waste or disposed of using the wastewater or sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dema found in:

A-Z Index: